Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1973 1
1976 2
1979 4
1980 3
1981 2
1982 3
1983 2
1984 1
1985 2
1986 1
1987 1
1988 1
1990 4
1991 1
1993 3
1994 5
1995 6
1996 5
1997 6
1998 2
1999 12
2000 5
2001 9
2002 8
2003 10
2004 9
2005 10
2006 6
2007 9
2008 8
2009 13
2010 19
2011 15
2012 19
2013 21
2014 14
2015 12
2016 8
2017 12
2018 11
2019 10
2020 11
2021 12
2022 12
2023 16
2024 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

327 results

Results by year

Filters applied: . Clear all
Page 1
Recruitment of FBXO22 for Targeted Degradation of NSD2.
Nie DY, Tabor JR, Li J, Kutera M, St-Germain J, Hanley RP, Wolf E, Paulakonis E, Kenney TMG, Duan S, Shrestha S, Owens DDG, Pon A, Szewczyk M, Lamberto AJ, Menes M, Li F, Barsyte-Lovejoy D, Brown NG, Barsotti AM, Stamford AW, Collins JL, Wilson DJ, Raught B, Licht JD, James LI, Arrowsmith CH. Nie DY, et al. Among authors: licht jd. bioRxiv [Preprint]. 2023 Nov 30:2023.11.01.564830. doi: 10.1101/2023.11.01.564830. bioRxiv. 2023. Update in: Nat Chem Biol. 2024 Dec;20(12):1597-1607. doi: 10.1038/s41589-024-01660-y. PMID: 37961297 Free PMC article. Updated. Preprint.
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.
Hogg SJ, Motorna O, Cluse LA, Johanson TM, Coughlan HD, Raviram R, Myers RM, Costacurta M, Todorovski I, Pijpers L, Bjelosevic S, Williams T, Huskins SN, Kearney CJ, Devlin JR, Fan Z, Jabbari JS, Martin BP, Fareh M, Kelly MJ, Dupéré-Richer D, Sandow JJ, Feran B, Knight D, Khong T, Spencer A, Harrison SJ, Gregory G, Wickramasinghe VO, Webb AI, Taberlay PC, Bromberg KD, Lai A, Papenfuss AT, Smyth GK, Allan RS, Licht JD, Landau DA, Abdel-Wahab O, Shortt J, Vervoort SJ, Johnstone RW. Hogg SJ, et al. Among authors: licht jd. Mol Cell. 2021 May 20;81(10):2183-2200.e13. doi: 10.1016/j.molcel.2021.04.015. Mol Cell. 2021. PMID: 34019788 Free PMC article.
Discovery of a Potent and Selective Targeted NSD2 Degrader for the Reduction of H3K36me2.
Hanley RP, Nie DY, Tabor JR, Li F, Sobh A, Xu C, Barker NK, Dilworth D, Hajian T, Gibson E, Szewczyk MM, Brown PJ, Barsyte-Lovejoy D, Herring LE, Wang GG, Licht JD, Vedadi M, Arrowsmith CH, James LI. Hanley RP, et al. Among authors: licht jd. J Am Chem Soc. 2023 Apr 12;145(14):8176-8188. doi: 10.1021/jacs.3c01421. Epub 2023 Mar 28. J Am Chem Soc. 2023. PMID: 36976643 Free PMC article.
Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture.
Yusufova N, Kloetgen A, Teater M, Osunsade A, Camarillo JM, Chin CR, Doane AS, Venters BJ, Portillo-Ledesma S, Conway J, Phillip JM, Elemento O, Scott DW, Béguelin W, Licht JD, Kelleher NL, Staudt LM, Skoultchi AI, Keogh MC, Apostolou E, Mason CE, Imielinski M, Schlick T, David Y, Tsirigos A, Allis CD, Soshnev AA, Cesarman E, Melnick AM. Yusufova N, et al. Among authors: licht jd. Nature. 2021 Jan;589(7841):299-305. doi: 10.1038/s41586-020-3017-y. Epub 2020 Dec 9. Nature. 2021. PMID: 33299181 Free PMC article.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD, Wong KK, Cerchietti L, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, Melnick AM. Béguelin W, et al. Among authors: licht jd. Cancer Cell. 2013 May 13;23(5):677-92. doi: 10.1016/j.ccr.2013.04.011. Cancer Cell. 2013. PMID: 23680150 Free PMC article.
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.
de Matos Simoes R, Shirasaki R, Downey-Kopyscinski SL, Matthews GM, Barwick BG, Gupta VA, Dupéré-Richer D, Yamano S, Hu Y, Sheffer M, Dhimolea E, Dashevsky O, Gandolfi S, Ishiguro K, Meyers RM, Bryan JG, Dharia NV, Hengeveld PJ, Brüggenthies JB, Tang H, Aguirre AJ, Sievers QL, Ebert BL, Glassner BJ, Ott CJ, Bradner JE, Kwiatkowski NP, Auclair D, Levy J, Keats JJ, Groen RWJ, Gray NS, Culhane AC, McFarland JM, Dempster JM, Licht JD, Boise LH, Hahn WC, Vazquez F, Tsherniak A, Mitsiades CS. de Matos Simoes R, et al. Among authors: licht jd. Nat Cancer. 2023 May;4(5):754-773. doi: 10.1038/s43018-023-00550-x. Epub 2023 May 26. Nat Cancer. 2023. PMID: 37237081 Free PMC article.
327 results